Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705916 | 0.85 | CHRM4 (0.69) | MEN1KMT2ACHRM4HRH3 | |
| SCHEMBL27943850 | 0.85 | MEN1 (0.65) | MEN1KMT2ASMN1; SMN2FAAHCCR3 | |
| SCHEMBL6704726 | 0.85 | MAPT (0.56) | CHRM4GAALMNAHRH3 | |
| SCHEMBL6223863 | 0.84 | SMN1; SMN2 (0.60) | MEN1KMT2ASMN1; SMN2FAAHCCR3 | |
| SCHEMBL14372316 | 0.82 | MEN1 (0.64) | MEN1KMT2AFAAHCCR3HRH3 | |
| SCHEMBL6705906 | 0.81 | MCHR1 (0.52) | MEN1KMT2ASMN1; SMN2CHRM4FAAH | |
| SCHEMBL6704534 | 0.81 | L3MBTL3 (0.59) | CHRM4 | |
| SCHEMBL6705907 | 0.80 | PRMT5 (0.52) | MEN1KMT2ASMN1; SMN2HRH3 | |
| SCHEMBL6702898 | 0.80 | CCR3 (0.68) | MEN1KMT2ASMN1; SMN2CHRM4CCR3 | |
| SCHEMBL6706014 | 0.80 | CHRM4 (0.54) | CHRM4GAAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | MEN1 995/4885KMT2A 406/4885SMN1; SMN2 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.